Farletuzumab (MORAb-003) is a humanized monoclonal antibody[1] of IgG1/κ[2] which is being investigated for the treatment of ovarian cancer.[3][4]
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Humanized |
| Target | FR-alpha |
| Clinical data | |
| Routes of administration | Intravenous injection |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C6466H9928N1716O2020S42 |
| Molar mass | 145371.06 g·mol−1 |
  (what is this?) (verify) | |
This drug was developed by Morphotek, Inc.
It is targeted at folate receptor alpha (FRα) which is overexpressed in some cancers such as epithelial ovarian cancer (EOC) and non-small-cell lung carcinoma.[2]
Mechanism of action edit
Farletuzumab uses the following mechanisms of action:[2]
Adverse effects edit
Common adverse effects include hypersensitivity reactions, fever, chills, headache, fatigue, and diarrhea.[2]
References edit
- ^ Statement On A Nonproprietary Name Adopted By The Usan Council - Farletuzumab, American Medical Association.
- ^ a b c d Sato S, Itamochi H (2016-03-07). "Profile of farletuzumab and its potential in the treatment of solid tumors". OncoTargets and Therapy. 9: 1181–8. doi:10.2147/OTT.S98242. PMC 4789847. PMID 27022278.
- ^ Clinical trial number NCT00738699 for "Phase II Efficacy and Safety Study of MORAb-003 in Platinum-Resistant or Refractory Relapsed Ovarian Cancer" at ClinicalTrials.gov
- ^ Clinical trial number NCT00849667 for "Phase III Efficacy and Safety of MORAb-003 in Subjects With Platinum-sensitive Ovarian Cancer in First Relapse" at ClinicalTrials.gov
 | This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it. |
 | This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it. |